[Children exposed to multidrug-resistant tuberculosis: How should we manage? Analysis of 46 child contacts and review of the literature]

Rev Pneumol Clin. 2015 Dec;71(6):335-41. doi: 10.1016/j.pneumo.2015.05.003. Epub 2015 Jul 17.
[Article in French]

Abstract

Introduction: Tuberculosis-related morbidity and mortality remain important. Emergence and diffusion of multidrug-resistance tuberculosis (MDR-TB) is a global public health concern. Cases of MDR-TB in children are a sentinel event indicating the spread of a mycobacterial strain within a community. Latent TB precedes MDR-TB and screening and follow-up of contact individuals are key points of TB infection control.

Methods: We performed the case-investigation of 20 adult cases of MDR-TB managed in our institution.

Results: Forty-six pediatric contact individuals were identified. A high proportion of these children were lost to follow-up (80% at 12 months), showing that monitoring this reservoir population with migrant history is challenging. Five (11%) children presented a secondary infection: one child was diagnosed with active TB infection (positive tuberculin skin test associated with abnormalities on chest computer tomography [CT] scan). Four children were diagnosed with latent TB infection (isolated positive tuberculin skin test with normal CT scan). Two of these children received a treatment adjusted to the strain of the index case.

Discussion: In the setting of emerging MDR-TB, tuberculin skin test may be likely replaced by specific interferon-gamma release assays (IGRA), independent of prior BCG vaccination. In addition, chest CT scan is preferred to chest X-ray to detect TB lesions. The management of latent TB infection is controversial: immediate treatment with second-line anti-TB drugs adapted to the index case strain or, consistently with WHO guidelines, a simple follow-up with subsequent treatment in case of active TB.

Keywords: Antituberculeux de seconde ligne; Antituberculosis preventive treatment; Enfants contacts; Infection tuberculeuse latente; Latent tuberculosis; Multidrug-resistant tuberculosis; Pediatric contact cases; Second-line antituberculosis drugs; Traitement préventif antituberculeux; Tuberculose multi-résistante.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Amikacin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • France / epidemiology
  • Humans
  • Infant
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy
  • Latent Tuberculosis / epidemiology
  • Levofloxacin / therapeutic use
  • Lost to Follow-Up
  • Male
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology*
  • Tuberculosis, Multidrug-Resistant / transmission*

Substances

  • Anti-Bacterial Agents
  • Levofloxacin
  • Amikacin